BONVIVA Injection of 3 ml solution contains 3 mg ibandronic acid (as sodium monohydrate). The concentration of ibandronic acid in the solution for injection is 1mg per ml.

Treatment of osteoporosis in postmenopausal women at increased risk of fracture.

A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.

Metabolic interactions are not considered likely, since ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and has been shown not to induce the hepatic cytochrome P450 system in rats. Ibandronic acid is eliminated by renal excretion only and does not undergo any biotransformation.

On the basis of the pharmacodynamic and pharmacokinetic profile and reported adverse reactions, it is expected that Bonviva has no or negligible influence on the ability to drive and use machines.